Monacounited States Helsinn Tender

Helsinn a Swiss pharmaceutical group focused on building quality cancer care and Lyfebulb a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease announced the opening of applications for their third annual Innovation Summit in Cancer. Candidates are invited to submit applications at httpslyfebulb.cominnovation-awardhelsinn-2020 where more information regarding eligibility criteria is available. Submissions may be made until November 17th 2019.The Summit is open to Patient Entrepreneurs building groundbreaking companies to advance the prevention diagnosis management or care of cancer. Patient Entrepreneurs include cancer patients cancer survivors or those having a close relative or loved one with cancer. Applicants for the competition must have established a company with impactful solutions to better manage and improve the quality of life of cancer patients with respect integrity and quality.While cancer is a broad-reaching disease the impact of it is felt very personally by each patient and his or her family said Karin Hehenberger MD PhD Founder and CEO of Lyfebulb. We look forward to seeing the latest innovators who have been personally impacted by this disease and turned this experience and the insights gained into much needed solutions for our community.The 2020 Lyfebulb-Helsinn Summit will be held at the Grimaldi Forum in Monaco on January 29th and 30th 2020 culminating in the announcement of the winner of the 2020 Lyfebulb-Helsinn Award of 25000 on January 30th during the 14th Monaco Biennale of Oncology. An additional 25000 Squinto-LePera Award in Oncology will also be awarded at that time.